Abstract
To the Editor: The role of surgical adjuvant radiation therapy for patients with cancer of the lung has been a subject of debate for many years. On the basis of fragmentary data from retrospective studies, we have recommended postoperative irradiation for patients with regional lymph-node metastasis (N1 and N2).1 The report by the Lung Cancer Study Group of its study of postoperative mediastinal irradiation has been eagerly awaited, since it was expected to clarify the issue. The publication of this study (Nov. 27 issue)2 leaves several important questions unanswered.The investigators chose to study only squamous-cell carcinoma in Stages II . . .